Home>Topics>Authors>Karen Andersen

Karen Andersen

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. The Friday Five

    Video Reports

    Fri, 28 Mar 2014

    teams focus on doing a better job in those two different verticals. Even though there might be some extra costs, Karen Andersen , whose is our Baxter analyst, thinks that overall this would probably be a pretty good deal. She's not planning

    Karen Andersen found at 5:50

    those two different verticals. Even though there might be some extra costs, Karen Andersen , whose is our Baxter analyst, thinks that overall this would probably be a pretty good deal. She's not planning on making any
  2. 10 High-Conviction Purchases by Our Ultimate Stock-Pickers

    Headlines

    Tue, 19 Nov 2013

    focused on the development of small molecule drugs for the treatment of infectious diseases. Morningstar analyst Karen Andersen expanded further on this commentary, noting that while she thinks that Gilead paid a steep premium to bring Pharmasset

  3. Announcing Morningstar's CEO of the Year Finalists

    Headlines

    Wed, 6 Nov 2013

    company into leading positions in the antifungal, HIV, and hepatitis C markets. Morningstar health-care analyst Karen Andersen expects Gilead's returns on invested capital to return to the mid-20% range by 2017 and believes that Gilead

  4. Gilead Sciences Carving Out a Wider Moat

    Headlines

    Thu, 8 Aug 2013

    recently sat down with senior biotechnology analyst Karen Andersen to discuss Gilead Sciences GILD. A few weeks ago ..... terms of growth potential and patent protection? Karen Andersen , senior biotechnology analyst: Gilead started out

  5. Insights From the 'Best on the Street'

    Video Reports

    Thu, 9 May 2013

    right now, and also to talk about some of their favorite picks for their radar screens in case there is a pullback. Karen Andersen : One of my favorite ideas right now is actually Gilead. It's a large-cap biotech name. We assign it a narrow

    Karen Andersen found at 3:14

    favorite picks for their radar screens in case there is a pullback. Karen Andersen : One of my favorite ideas right now is actually Gilead. It's a large-cap biotech name. We assign it a narrow-moat rating, and
  6. J&J to Swallow Vaccine Maker Crucell

    Commentary

    Fri, 17 Sep 2010

    short term. More important, over the long term, we believe Crucell's vaccine platform and novel biologics manufacturing platform open the door to major new markets for Johnson & Johnson. Karen Andersen , CFA, contributed to this note.

  7. Sanofi Reveals Bid for Genzyme

    Commentary

    Mon, 30 Aug 2010

    AMGN, to emerge in the coming weeks. Given the timing of other acquisitions--such as Eli Lilly's LLY acquisition of ImClone--we think a deal could get done in September or October. Karen Andersen , CFA, contributed to this note.

  8. Lilly Halts Alzheimer's Drug

    Commentary

    Tue, 17 Aug 2010

    solanezumab. However, we only project a 40% chance of approval for solanezumab, based on the scientific community's lack of understanding of the mechanism of Alzheimer's disease. Karen Andersen , CFA, contributed to this note.

  9. GE and Geron Team Up in Stem Cells

    Commentary

    Tue, 30 Jun 2009

    use of stem-cell treatment of spinal cord injuries in humans. As discussed by Morningstar biotechnology analyst Karen Andersen in the June issue of the Morningstar Healthcare Observer , Geron's spending in the area of stem-cell research

  10. Gilead Offers to Buy CV Therapeutics

    Commentary

    Thu, 12 Mar 2009

    now poised for even stronger long-term growth. We will dig further into the details of this deal and publish updates for both Gilead and CV Therapeutics when more information becomes available. Karen Andersen contributed to this note.

« Prev12Next »
Content Partners